Center for International Blood and Marrow Transplant Research
39
9
16
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.3%
4 terminated/withdrawn out of 39 trials
81.0%
-5.5% vs industry average
5%
2 trials in Phase 3/4
24%
4 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (39)
Menin-Inhibitor Targeted Maintenance in AML
Role: lead
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Role: lead
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Role: lead
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Role: lead
Conditioning SCID Infants Diagnosed Early
Role: lead
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Role: collaborator
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Role: lead
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
Role: collaborator
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Role: lead
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Role: lead
CIBMTR Research Database
Role: lead
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Role: lead
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Role: lead
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
Role: collaborator
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Role: collaborator
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Role: lead
Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors
Role: lead
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Role: collaborator
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
Role: lead
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Role: lead